相似文献
1
Systemic targeted therapy beyond sorafenib.
Clin Liver Dis (Hoboken). 2013 Jan 23;1(6):212-216. doi: 10.1002/cld.128. eCollection 2012 Dec.
2
Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
Chin Clin Oncol. 2018 Oct;7(5):50. doi: 10.21037/cco.2018.10.10.
3
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26.
4
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
J Clin Gastroenterol. 2014 Mar;48(3):e22-9. doi: 10.1097/MCG.0b013e3182a54ec8.
5
Systemic Therapy for Hepatocellular Carcinoma: 2017 Update.
Oncology. 2017;93 Suppl 1:135-146. doi: 10.1159/000481244. Epub 2017 Dec 20.
6
Locoregional and systemic therapy for hepatocellular carcinoma.
J Gastrointest Oncol. 2017 Apr;8(2):215-228. doi: 10.21037/jgo.2017.03.13.
7
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Expert Opin Investig Drugs. 2010 May;19(5):663-72. doi: 10.1517/13543781003767426.
8
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Oncotarget. 2017 Jul 18;8(29):47555-47564. doi: 10.18632/oncotarget.17733.
9
Is the era of sorafenib over? A review of the literature.
Ther Adv Med Oncol. 2020 May 26;12:1758835920927602. doi: 10.1177/1758835920927602. eCollection 2020.
10
Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
Anticancer Res. 2019 Feb;39(2):1067-1072. doi: 10.21873/anticanres.13214.
引用本文的文献
1
Application of Trifluoroacetic Acid as a Theranostic Agent for Chemical Ablation of Solid Tissue.
J Vasc Interv Radiol. 2020 Jan;31(1):169-175. doi: 10.1016/j.jvir.2019.05.002. Epub 2019 Sep 16.
2
Temperature mapping of exothermic chemistry: imaging of thermoembolization via MR.
Int J Hyperthermia. 2019;36(1):730-738. doi: 10.1080/02656736.2019.1635274.
本文引用的文献
1
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Clin Cancer Res. 2012 Apr 1;18(7):2090-8. doi: 10.1158/1078-0432.CCR-11-1991. Epub 2012 Jan 11.
2
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Cancer. 2011 Nov 15;117(22):5094-102. doi: 10.1002/cncr.26165. Epub 2011 Apr 27.
3
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
4
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Clin Cancer Res. 2011 Apr 1;17(7):1973-83. doi: 10.1158/1078-0432.CCR-10-2011. Epub 2011 Feb 24.
5
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
JAMA. 2010 Nov 17;304(19):2154-60. doi: 10.1001/jama.2010.1672.
6
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Cancer J. 2009 Jul-Aug;15(4):263-8. doi: 10.1097/PPO.0b013e3181af5e35.
7
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
Lancet Oncol. 2009 Aug;10(8):794-800. doi: 10.1016/S1470-2045(09)70171-8. Epub 2009 Jul 6.
8
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
J Clin Oncol. 2009 Feb 20;27(6):843-50. doi: 10.1200/JCO.2008.18.3301. Epub 2009 Jan 12.
9
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
10
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件